Výsledky vyhledávání - "Sanner, Mark A"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer’s disease

Autor: Kristin Kelly, Christopher John Helal, Tate Bonnie Frances, Mavis Diane Adam, Zhijun Kang, Marcia F. Peterson, Thomas G. Gant, Christopher B. Cooper, Michael K. Ahlijanian, Stanley William Kupchinsky, John C. Lucas, Frank S. Menniti, Sanner Mark Allen

Publikováno v: Bioorganic & Medicinal Chemistry Letters. 14:5521-5525

High-throughput screening with cyclin-dependent kinase 5 (cdk5)/p25 led to the discovery of N-(5-isopropyl-thiazol-2-yl)isobutyramide (1). This compound is an equipotent inhibitor of cdk5 and cyclin-dependent kinase 2 (cdk2)/cyclin E (IC50 = ca. 320

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1a7b171a8387e73aea99641b4e26b53
https://doi.org/10.1016/j.bmcl.2004.09.006

Zobrazit plný text záznamu

Tau Protein Phosphorylation as a Therapeutic Target in Alzheimers Disease

Autor: Joel B. Schachter, Sanner Mark Allen, Lit-Fui Lau, Patricia A. Seymour

Publikováno v: Current Topics in Medicinal Chemistry. 2:395-415

Neurofibrillary tangles (NFTs) are a distinguishing neuropathological feature found in postmortem brains of Alzheimer s disease (AD) and tauopathy patients. The density of these lesions correlates with severity of AD and their distribution follows a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01eaa040961dc4e19eb2315e1f479f12
https://doi.org/10.2174/1568026024607526

Zobrazit plný text záznamu

Selective dopamine D4 receptor antagonists

Autor: Sanner Mark Allen

Publikováno v: Expert Opinion on Therapeutic Patents. 8:383-393

The discovery that the atypical antipsychotic clozapine has higher affinity for the dopamine D4 receptor relative to the D2 receptor touched off a search for more potent, highly selective D4 antagonists as a new class of antipsychotics. Many compound

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a32587b2f0f7c7efdf4064b959111dd
https://doi.org/10.1517/13543776.8.4.383

Zobrazit plný text záznamu

Selective dopamine D 4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition

Autor: Elizabeth W. Brooks, Robert S. Mansbach, Stevin H. Zorn, Sanner Mark Allen

Publikováno v: Psychopharmacology. 135:194-200

Recent evidence suggests that the dopamine D4 receptor may play a role in schizophrenia, and that the atypical properties of the antipsychotic clozapine may be attributable in part to its antagonistic actions at this receptor. In the present study, c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fe445d6129ec39457894dabb32fe491
https://doi.org/10.1007/s002130050501

Zobrazit plný text záznamu

The discovery of potent and selective dopamine D4 receptor antagonists

Autor: Stevin H. Zorn, Fliri Anton F J, Sanner Mark Allen, W. Stephen Faraci

Publikováno v: Current Opinion in Chemical Biology. 2:535-540

The identification of a novel dopamine receptor subtype, referred to as the D4 receptor, which binds the atypical antipsychoti drug clozapine with high potency, has led to the initiation of a drug discovery program that aims to find novel inhibitors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c45b75b4e8f0f520b24087e458015c7e
https://doi.org/10.1016/s1367-5931(98)80131-2

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání